



Article Trypsin Genes Are Regulated through the miRNA Bantam and Associated with Drug Sensitivity in the Sea Louse Caligus rogercresseyi

Gustavo Núñez-Acuña ^{1,2,*}, Valentina Valenzuela-Muñoz ^{1,2}, Crisleri Carrera-Naipil ^{1,2}, Constanza Sáez-Vera ^{1,2}, Bárbara P. Benavente ^{1,2}, Diego Valenzuela-Miranda ^{1,2} and Cristian Gallardo-Escárate ^{1,2}

- ¹ Interdisciplinary Center for Aquaculture Research (INCAR), University of Concepción, Concepción P.O. Box 160-C, Chile; valevalenzuela@udec.cl (V.V.-M.); crislericarrera@gmail.com (C.C.-N.); saezvera.c@gmail.com (C.S.-V.); bbenavente@udec.cl (B.P.B.); divalenzuela@udec.cl (D.V.-M.); crisgallardo@udec.cl (C.G.-E.)
- ² Laboratory of Biotechnology and Aquatic Genomics, Department of Oceanography, University of Concepción, Concepción P.O. Box 160-C, Chile
- * Correspondence: gustavonunez@udec.cl; Tel.: +56-44-2661618

Abstract: The role of *trypsin* genes in pharmacological sensitivity has been described in numerous arthropod species, including the sea louse Caligus rogercresseyi. This ectoparasite species is mainly controlled by xenobiotic drugs in Atlantic salmon farming. However, the post-transcriptional regulation of trypsin genes and the molecular components involved in drug response remain unclear. In particular, the miRNA bantam family has previously been associated with drug response in arthropods and is also found in C. rogercresseyi, showing a high diversity of isomiRs. This study aimed to uncover molecular interactions among trypsin genes and bantam miRNAs in the sea louse C. rogercresseyi in response to delousing drugs. Herein, putative mRNA/miRNA sequences were identified and localized in the C. rogercresseyi genome through genome mapping and blast analyses. Expression analyses were obtained from the mRNA transcriptome and small-RNA libraries from groups with differential sensitivity to three drugs used as anti-sea lice agents: azamethiphos, deltamethrin, and cypermethrin. The validation was conducted by qPCR analyses and luciferase assay of selected bantam and trypsin genes identified from in silico transcript prediction. A total of 60 trypsin genes were identified in the C. rogercresseyi genome, and 39 bantam miRNAs were differentially expressed in response to drug exposure. Notably, expression analyses and correlation among values obtained from *trypsin* and *bantam* revealed an opposite trend and potential binding sites with significant ΔG values. The luciferase assay showed a reduction of around 50% in the expression levels of the trypsin 2-like gene, which could imply that this gene is a potential target for bantam. The role of trypsin genes and bantam miRNAs in the pharmacological sensitivity of sea lice and the use of miRNAs as potential markers in these parasites are discussed in this study.

Keywords: bantam; trypsin; drug sensitivity; pharmacological resistance; sea lice; Caligus rogecresseyi

1. Introduction

The most relevant infectious disease caused by an ectoparasite species in the Chilean farmed salmon industry is Caligidosis [1]. The infective agent of this disease is the marine copepod *Caligus rogercresseyi*, which is widely distributed in salmon farms in Southern Chile [2,3]. The losses caused by Caligidosis to the salmon industry are in the order of hundreds of millions of US dollars per year [4,5]. The control for this disease mainly consists of drug treatments, including organophosphate, pyrethroid, and avermectin molecules [6,7]. However, the control by the use of these molecules has been threatened by the emergence of pharmacological resistance in *Lepeophtheirus salmonis* [8] and the reduced efficacy reported in *C. rogercresseyi* [9,10]. This evidence is supported by the identification of putative drug detoxification systems and excretion mechanisms found in sea lice species [11].



Citation: Núñez-Acuña, G.; Valenzuela-Muñoz, V.; Carrera-Naipil, C.; Sáez-Vera, C.; Benavente, B.P.; Valenzuela-Miranda, D.; Gallardo-Escárate, C. Trypsin Genes Are Regulated through the miRNA Bantam and Associated with Drug Sensitivity in the Sea Louse *Caligus rogercresseyi. Non-coding RNA* **2021**, *7*, 76. https://doi.org/10.3390/ ncrna7040076

Academic Editor: George A Calin

Received: 12 October 2021 Accepted: 30 November 2021 Published: 3 December 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). The molecular mechanisms behind pharmacological resistance are not yet wholly described in marine ectoparasites. In terrestrial arthropods, pharmacological resistance mechanisms involve mutations in target genes, drug detoxification and metabolism, and morphological variations [12–14]. In sea lice species, mutations in target genes for delousing drugs have been associated with resistant genotypes in *L. salmonis* widely distributed among the Northern Hemisphere coasts [15,16]. However, recent studies applying next-generation sequencing techniques have described diverse and complex molecular responses that suggest novel pharmacological resistance mechanisms in the sea louse *C. rogercresseyi* [11,17,18]. Among these genes, *trypsins* are a group of genes involved in drug detoxification and differentially expressed in *C. rogercresseyi* exposed to azamethiphos and deltamethrin drugs [19]. These genes are present in the secretory / excretory products (SEPs) in ectoparasites [20,21]. From *trypsins*, 44 different isoforms have been described in *C. rogercresseyi* [19]. In addition, two isoforms of *trypsin* genes showed strong transcriptional differences between susceptible and resistant lice strains to the pesticide deltamethrin. Notably, findings have suggested putative molecular interactions with non-coding genes [11].

The molecular mechanisms behind pharmacological resistance are not exclusive to coding genes. Non-coding RNAs, including miRNAs, have a role in drug exposure responses and pharmacological resistance in several species [22]. For example, in arthropods, miRNAs regulate the expression of genes related to drug detoxication, conferring pharmacological resistance to drugs such as chlorantraniliprole [23] and pyrethroids [24,25]. In the sea louse *C. rogercresseyi*, previous investigations identified the whole miRNome and its association with ontogeny development during its lifecycle [26]. One of the most abundant families of miRNAs is *bantam*, which is highly up-regulated in the infective developmental stage of this parasite (copepodid). A newer version of the *C. rogercresseyi* miRNome has just been published, and an association with resistant strains to three delousing drugs was found [27]. In this study, *bantam* was also described as a key miRNA family, putatively interacting with genes related to drug detoxication. The differentially expressed miRNAs in lice exposed to delousing were also putatively associated with long non-coding RNAs (lncRNAs). This class of non-coding RNAs has also been identified as having a potential role in the drug response [28].

The objective of this study was to identify, evaluate, and validate the putative molecular interactions among *trypsin* genes and *bantam* miRNAs in the sea louse *C. rogercresseyi* exposed to delousing drugs. These genes were selected as candidates based on previous evidence related to their abundance and role in drug responses of *trypsins* and *bantam*. Furthermore, previous research in other arthropod species has described potential interactions of novel miRNAs—bantam included—with serine protease genes [29]. However, this is the first study to explore the molecular interplay between miRNA *bantam* and mRNA *trypsin* in sea lice, and their putative roles in drug response and pharmacological resistance.

2. Results

2.1. Identification of Trypsin Genes and Bantam miRNAs in the C. rogercresseyi Genome

A total of 60 trypsin genes were mapped and annotated in the genome of *C. rogercresseyi*. These genes were distributed in the 21 chromosomes, but the mapped reads were mainly located at chromosomes 3, 1, 10, and 11 (Figure 1). The gene lengths were highly divergent among the trypsins, where the shortest was a chymotrypsin-like elastase family member with 315 bp located in chromosome 5, and the longest was trypsin-1 with 44,817 bp located in chromosome 13 (Table 1). Thus, the average length of trypsin genes was 4518 bp. Genes with multiple transcripts were also abundant, ranging from 1 to 7 transcripts per gene. The shortest transcript coding for a trypsin mRNA was 240 nt in length, and the most extended identified transcript had a length of 4522 nt. Thus, the average length for transcripts coding for trypsins was 1042 nt. The direction of transcripts was inferred in 43 trypsin genes, where 22 were identified in the positive (+) and 21 in the negative strand (-).

Typpsin-1 Chr2 543 - 1 871 Strine protoce 48-like Chr5 4377 + 7 508 Strine protoce 58-like Chr5 4377 + 7 508 Typpsin 1-like Chr5 4377 + 7 508 Strine protoce 58-like Chr5 4377 + 7 508 Strine protoce 58-like Chr5 4377 + 7 508 Strine protoce 58-like Chr5 4377 + 7 508 Strine protoce 576 Sike Chr5 4377 + 7 508 Strine protoce 576 Sike Chr5 4377 + 2 862 Typpsin 7 Chr6 185 - 2 593 Amoric typpsin 13 Chr10 365 - 1 1280 Inter stypesin 143 Chr19 359 - 4 240 Inter stypesin 143 Chr19 359 -	Gene Name	Chromosome	Length (bp)	Strand	Transcripts	Transcript Length
Typesin 3-fike Chu5 5134 - 1 1330 Serine protoces 45 like Chu5 4377 + 7 508 Serine protoces 53-like Chu5 4377 + 7 508 Typesin 1-like Chu5 4377 + 7 508 Typesin 2-like Chu5 4377 + 7 508 Chymerry mode 33-like Chu5 4377 + 7 508 Chymerry mode 33-like Chu5 4377 + 7 508 Chymerry mode 31-like Chu6 4387 - 2 862 Typesin 2 Chu6 1885 - 2 459 Typesin 4 Chu70 1885 - 2 452 Typesin 112 Chu10 1397 + 1 1200 Inter alpha trypesin 113 Chu19 4865 + 2 452 Inter alpha trypesin 14 Chu19 329 - 4 240	Trypsin-1	Chr2	5343	_	1	871
Scribe probase 3-Bike Chr.5 4377 + 7 508 Tygsin 1-1ke Chr.5 4377 + 7 508 Tygsin 1-1ke Chr.5 4377 + 7 508 Seriue protose 53-like Chr.5 4377 + 7 508 Chynotrypsin 2-like Chr.5 4377 + 7 508 Chynotrypsin 2-like Chr.5 4377 + 7 508 Chynotrypsin 2-like Chr.5 4377 + 7 508 Typsin 1 Chr.6 1885 - 2 862 Typsin 1 Chr.6 1885 - 2 559 Anionic trypsin 1-2 Chr.10 365 7 1 1200 Inter -sliph-trypsin 1-3 Chr.15 8195 + 2 4522 Inter -sliph-trypsin 1-4 Chr.19 4865 + 2 4522 Inter -sliph-trypsin 1-4 Chr.19 329 - 4	Trypsin-3-like	Chr5	5134	-	1	1330
Strite probase 53-lake Chr5 4377 + 7 508 Trypsin 1-1ke Chr5 4377 + 7 508 Strite probase 53-lake Chr5 4377 + 7 508 Opmotrysin 2-1ke Chr5 4377 + 7 508 Opmotrysin 2-1ke Chr6 7501 + 2 862 Trypsin 7 Chr6 7501 + 2 850 Trypsin 7 Chr6 7501 + 2 850 Trypsin 7 Chr6 1885 - 2 283 Trypsin 12 Chr10 1875 + 1 1288 Inter-solphot-trypsin 144 Chr19 4865 + 2 4522 Inter-solphot-trypsin 144 Chr19 329 - 4 240 Inter-solphot-trypsin 144 Chr19 329 - 4 240 Inter-solphot-trypsin 145 Chr19 329 - 4 240	Serine protease 48-like	Chr5	4377	+	7	508
Trgsin 1-Mac Chr5 4377 + 7 508 Serice probase 53-Mac Chr5 4377 + 7 508 Protexas serice probase 53-Mac Chr5 4377 + 7 508 Chymbryphin-2-Like Chr5 4377 + 7 508 Tygsin 2 Chr6 7501 + 2 862 Tygsin 3 Chr6 1885 - 2 539 Trgsin 4 Chr6 1885 - 2 2433 Irreshin 1/rspin 2 Chr10 1357 + 1 1286 Antomic trypsin 2 Chr10 1357 + 2 2433 Irreshin 1/rspin 14 Chr19 3257 + 1 1286 Inter alphin-trypsin 14 Chr19 329 - 4 240 Inter alphin-trypsin 14 Chr19 329 - 4 240 Inter alphin-trypsin 14 Chr19 329 - 4 240	Serine protease 53-like	Chr5	4377	+	7	508
Tagsin 1-like Chr5 4377 + 7 508 Protasse serine 9-like Chr5 4377 + 7 508 Opunotryspin-2-like Chr5 4377 + 7 508 Tryssin-7 Chr6 7501 + 2 862 Tryssin-7 Chr6 7501 + 2 852 Tryssin Chr6 1885 - 2 359 Animatri tryson-2 Chr10 365 7 1 368 Tryssin 1172 Chr18 8255 + 1 1280 Tryssin 11722 Chr19 4865 + 2 4522 Inter-alphot-tryspin 14 Chr19 329 - 4 240 Inter-alphot-tryspin 14 Chr19 329 - 4 240 Inter-alphot-tryspin 14 Chr19 329 - 4 240 Inter-alphot-tryspin 15 Chr19 329 - 4 240 <tr< td=""><td>Trypsin-1-like</td><td>Chr5</td><td>4377</td><td>+</td><td>7</td><td>508</td></tr<>	Trypsin-1-like	Chr5	4377	+	7	508
Serine protoxe 53-like Chr5 4377 + 7 508 Chynotrysin-2-like Chr5 4377 + 7 508 Chynotrysin-2-like Chr6 7501 + 2 862 Tryssin-7 Chr6 7501 + 2 859 Tryssin Chr6 1885 - 2 559 Anomic tryssin-2 Chr10 1367 + 1 1208 Anomic tryssin-2 Chr10 1397 + 1 1208 Inter-alpha-tryssin IH Chr19 4865 + 2 452 Inter-alpha-tryssin IH Chr19 329 - 4 200 Inter-alpha-tryssin IH Chr19 329 - 4 200 Inter-alpha-tryssin IH Chr19 329 - 4 200 Inter-alpha-tryssin IH Chr1 1208 + 1 708 Inter-alpha-tryssin IH Chr1 1208 + 1	Trypsin-1-like	Chr5	4377	+	7	508
Partasessime 3-like Chr5 4377 + 7 508 Trygsin-2-like Chr6 7501 + 2 862 Trygsin Chr6 7501 + 2 859 Trygsin Chr6 1885 - 2 559 Anionic trygsini-2 Chr10 365 ? 1 365 Anionic trygsini-2 Chr10 1397 + 1 1268 Inter-siphe-trygsin H3 Chr15 8195 + 2 4522 Inter-siphe-trygsin H4 Chr19 3865 + 2 4522 Inter-siphe-trygsin H4 Chr19 329 - 4 240 Inter-siphe-trygsin H4 Chr1 108 - 1018 <t< td=""><td>Serine protease 53-like</td><td>Chr5</td><td>4377</td><td>+</td><td>7</td><td>508</td></t<>	Serine protease 53-like	Chr5	4377	+	7	508
Chrysin-2-läc Chr5 4377 + 7 508 Tygsin-7 Chr6 7501 + 2 862 Tygsin Chr6 7501 + 2 859 Tygsin Chr6 1885 - 2 559 Tygsin Chr6 1885 - 2 453 Antonic trygsin 12 Chr10 1397 + 1 1268 Inter-alpha-trygsin 13 Chr18 5255 + 1 1200 Inter-alpha-trygsin 144 Chr19 3485 + 2 4522 Inter-alpha-trygsin 144 Chr19 329 - 4 2400 Inter-alpha-trygsin 15 Chr19 329 - 4 240 Inter-alpha-trygsin 165 Chr19 329 - 4 240 Inter-alpha-trygsin 17 Chr1 1208 + 1 018 Antonic trygsin 14 Chr5 344 ? 1 343	Protease serine 9-like	Chr5	4377	+	7	508
Trgsiri-2 Chr6 7501 + 2 862 Trgsiri Chr6 1885 - 2 559 Trgsiri Chr6 1885 - 2 559 Antonic trgsin: 2 Chr10 365 ? 1 365 Inter-alpha-trgsin H3 Chr15 8195 + 2 2433 Inter-alpha-trgsin H4 Chr19 4865 + 2 4522 Inter-alpha-trgsin H4 Chr19 329 - 4 240 Inter-alpha-trgsin H4 Chr19 329 - 4 240 Inter-alpha-trgsin H5 Chr19 329 - 4 240 Inter-alpha-trgsin H4 Chr19 329 - 4 240 Inter-alpha-trgsin H4 Chr1 108 + 1 1018 Inter-alpha-trgsin H4 Chr5 340 ? 1 3430 Cignardrgsin H4 Chr5 496 - 1 427 <td>Chymotrypsin-2-like</td> <td>Chr5</td> <td>4377</td> <td>+</td> <td>7</td> <td>508</td>	Chymotrypsin-2-like	Chr5	4377	+	7	508
Typpsin-7 Chró 7501 + 2 652 Typpsin Chró 1885 - 2 559 Anionic typpsin-2 Chrí 0 365 - 1 365 Anionic typpsin-2 Chrí 0 1397 + 1 1268 Inter-alpha-trypsin H3 Chrí 5 8195 + 2 2452 Inter-alpha-trypsin H4 Chrí 9 329 - 4 2400 Inter-alpha-trypsin H4 Chrí 9 329 - 4 240 Inter-alpha-trypsin H5 Chrí 9 329 - 4 240 Inter-alpha-trypsin H6 Chrí 9 329 - 4 240 Inter-alpha-trypsin H6 Chrí 1 288 + 1 0108 Anionic trypsin-1 Chrí 1 831 - 1 343 Chymotrypsin K6 Chrí 5 344 ? 1 343 Chymotrypsin K6 Chrí 5 807 ? 2 <	Trypsin-2	Chr6	7501	+	2	862
Trgspin Chró 1885 - 2 559 Anionic tryspin-2 Chr10 365 ? 1 365 Anionic tryspin-2 Chr10 1397 + 1 1288 Inter-alpha-tryspin H3 Chr18 5255 + 1 1290 Inter-alpha-tryspin H4 Chr19 4865 + 2 4522 Inter-alpha-tryspin H4 Chr19 329 - 4 2400 Inter-alpha-tryspin H3 Chr19 329 - 4 240 Inter-alpha-tryspin H5 Chr19 329 - 4 240 Inter-alpha-tryspin H5 Chr19 329 - 4 240 Inter-alpha-tryspin H4 Chr19 329 - 1 343 Inter-alpha-tryspin H4 Chr1 200 343 </td <td>Trypsin-7</td> <td>Chr6</td> <td>7501</td> <td>+</td> <td>2</td> <td>862</td>	Trypsin-7	Chr6	7501	+	2	862
Trypsin Chró 1885 - 2 559 Anionic trypsin-2 Chr10 1397 + 1 1268 Inter-alpha-trypsin H3 Chr15 8195 + 1 1200 Inter-alpha-trypsin H4 Chr19 8485 + 2 4522 Inter-alpha-trypsin H4 Chr19 329 - 4 240 Inter-alpha-trypsin H4 Chr19 329 - 4 240 Inter-alpha-trypsin H4 Chr19 329 - 4 240 Inter-alpha-trypsin H5 Chr19 329 - 4 240 Inter-alpha-trypsin H4 Chr19 329 - 4 240 Inter-alpha-trypsin H4 Chr1 331 - 1 315 Inter-alpha-trypsin H4 Chr1 3430 ? 1 3430 Chymotrystopsin B Chr5 315 ? 1 315 Inter-alpha-trypsin H4 Chr5 367 ? 2 593 Chymotrystopsin B Chr5 807 ?	Trypsin	Chr6	1885	—	2	559
Anionic trygsin-2 Chr10 365 ? 1 365 Inter-alpha-trygsin H3 Chr10 1397 + 1 1268 Inter-alpha-trygsin H4 Chr18 5255 + 1 1290 Inter-alpha-trygsin H4 Chr19 4865 + 2 4522 Inter-alpha-trygsin H4 Chr19 329 - 4 240 Inter-alpha-trygsin H4 Chr19 329 - 4 240 Inter-alpha-trygsin H5 Chr19 329 - 4 240 Inter-alpha-trygsin H4 Chr19 329 - 4 240 Inter-alpha-trygsin H4 Chr19 329 - 4 340 Olymotrygsin-1 Chr1 108 341 1 1018 Anionic trygsin-1 Chr1 343 ? 1 345 Olymotrygsin-16k Chr3 340 ? 1 345 Olymotrygsin-2ke Chr5 807 ? 2	Trypsin	Chr6	1885	—	2	559
Anionic trypsin-2 Chr 10 1397 + 1 1268 Inter-alpla-trypsin H4 Chr 15 8195 + 1 1290 Inter-alpla-trypsin H4 Chr 19 4865 + 2 4522 Inter-alpla-trypsin H4 Chr 19 329 - 4 240 Inter-alpla-trypsin H5 Chr 19 329 - 4 240 Inter-alpla-trypsin H5 Chr 19 329 - 4 240 Inter-alpla-trypsin H6 Chr 19 329 - 4 240 Inter-alpla-trypsin H5 Chr 1 1208 + 1 1018 Anionic trypsin-1 Chr 1 1208 + 1 3430 Inter-alpla-trypsin H4 Chr 3 3430 ? 1 3431 Chynotrypsin-ger B Chr 5 135 ? 1 346 Chynotrypsin-S Chr 5 164 + 1 346 Chynotrypsin-S Chr 5 807 ?	Anionic trypsin-2	Chr10	365	?	1	365
Inter-alpha-trapsin H3 Chr15 8195 + 2 2453 Inter-alpha-trapsin H4 Chr19 3255 + 1 1290 Inter-alpha-trapsin H4 Chr19 329 - 4 240 Inter-alpha-trapsin H3 Chr19 329 - 4 240 Inter-alpha-trapsin H4 Chr19 329 - 4 240 Inter-alpha-trapsin H5 Chr19 329 - 4 240 Inter-alpha-trapsin H4 Chr1 343 - 1 313 Chr1 B205 K 1 3430 2 1 343 Chr10 Chr5 343 ? 1 345 1 345 Chr10 Kr5	Anionic trypsin-2	Chr10	1397	+	1	1268
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Inter-alpha-trypsin H3	Chr15	8195	+	2	2453
Indir-alpha-trypsin H4 Chrl 19 4865 + 2 4522 Inter-alpha-trypsin H3 Chrl 19 329 - 4 240 Inter-alpha-trypsin H3 Chrl 19 329 - 4 240 Inter-alpha-trypsin H4 Chrl 19 329 - 4 240 Inter-alpha-trypsin H4 Chrl 1 1008 + 1 1018 Anionic trypsin H4 Chrl 1 831 - 1 3430 Inter-alpha-trypsin H4 Chrl 3 3430 ? 1 3430 Chymotrypsin-2ike Chrl 3 343 ? 1 3430 Chymotrypsin-bike Elastes Chrl 5 448 + 1 345 Anionic trypsin-2ike Chrl 5 614 + 1 545 Anionic trypsin-2ike Chrl 5 807 ? 2 593 Chymotrypsin-2ike Chrl 10 756 - 1 646 Trypsin ch Chrl 2 668	Trypsin II-P29	Chr18	5255	+	1	1290
Inter-alpha-trypsin H3 Chrl 9 4865 + 2 4522 Inter-alpha-trypsin H3 Chrl 9 329 - 4 240 Inter-alpha-trypsin H4 Chrl 9 329 - 4 240 Inter-alpha-trypsin H5 Chrl 9 329 - 4 240 Inter-alpha-trypsin H5 Chrl 1 1008 + 1 1018 Anionic trypsin -1 Chrl 1 1008 + 1 703 Inter-alpha-trypsin H4 Chr3 3430 ? 1 3430 Chymotrypsin-Sike Chr5 315 ? 1 356 Chymotrypsin-B Chr5 448 + 1 386 Anionic trypsin-2-like Chr5 807 ? 2 593 Chymotrypsin-14k Chr5 807 ? 2 593 Chymotrypsin-14k Chr10 7596 - 1 646 Trypsin eta Chr12 668 ? 1	Inter-alpha-trypsin H4	Chr19	4865	+	2	4522
Inter-alpha-trypsin H3 Chrl 9 329 - 4 240 Inter-alpha-trypsin H4 Chrl 9 329 - 4 240 Inter-alpha-trypsin H5 Chrl 9 329 - 4 240 Inter-alpha-trypsin H6 Chrl 1 108 + 1 1018 Anionic trypsin-1 Chrl 1 100 7 1 3430 Chymotrypsin Ba Chr3 343 ? 1 315 Chymotrypsin Ba Chr5 315 ? 1 315 Chymotrypsin-1ke Lastase Chr5 448 + 1 545 Anionic trypsin-2-like Chr5 496 - 1 427 Trypsin eta Chr5 807 ? 2 593 Clymotrypsin-like Chr10 7596 - 1 385 Trypsin-like Chr13 646 ? 1 668 Trypsin-like Chr13 264 - 2 345 <td>Inter-alpha-trypsin H4</td> <td>Chr19</td> <td>4865</td> <td>+</td> <td>2</td> <td>4522</td>	Inter-alpha-trypsin H4	Chr19	4865	+	2	4522
Inter-alpha-trypsin H4 Chr19 329 - 4 240 Inter-alpha-trypsin H6 Chr1 1008 + 1 1018 Aniomic trypsin-1 Chr1 831 - 1 3430 Chymotrypsinsogen B Chr5 315 ? 1 355 Chymotrypsin-Serike Chr5 614 + 1 545 Aniomic trypsin-2-like Chr5 807 ? 2 593 Trypsin eta Chr5 807 ? 2 593 Chymotrypsin-Hke Chr10 796 - 1 985 BYTIKumitz protein Chr12 668 ? 1 668 Trypsin-like Chr13 2764 - 2 3	Inter-alpha-trypsin H3	Chr19	329	-	4	240
Inter-alpha-trypein H5 Chr19 329 - 4 240 Trypsin-1 Chr1 1208 + 1 1018 Anionic trypsin-1 Chr1 831 - 1 703 Inter-alpha-trypsin H4 Chr3 3330 ? 1 334 Chymotrypsingen B Chr5 315 ? 1 334 Chymotrypsin H6 Elsasse Chr5 448 + 1 386 Anionic trypsin-2-like Chr5 614 + 1 386 Anionic trypsin-2-like Chr5 496 - 1 427 Trypsin c1 Chr5 807 ? 2 593 Trypsin c1 Chr5 807 ? 1 385 DPT/Jkonitz Chr10 7596 - 1 668 Trypsin-1 Chr12 668 ? 1 668 Trypsin-like Chr13 2/64 - 2 345 <	Inter-alpha-trypsin H4	Chr19	329	-	4	240
Inter-diplos-trypsin H6 Chr19 329 - 4 240 Trypsin-1 Chr1 1208 + 1 1018 Anionic trypsin-1 Chr1 831 - 1 703 Inter-adpha-trypsin H4 Chr3 3430 ? 1 3430 Chymotrypsin-ike Elastase Chr5 315 ? 1 355 Chymotrypsin-ike Elastase Chr5 418 + 1 356 Anionic trypsin-2-like Chr5 614 + 1 545 Anionic trypsin-2-like Chr5 614 + 1 356 Anionic trypsin-2-like Chr5 807 ? 2 593 Trypsin cla Chr5 807 ? 2 593 Trypsin cla Chr10 756 - 1 845 PhytiKunitz protein Chr12 668 ? 1 668 Trypsin-like Chr13 2764 - 2 345 <td>Inter-alpha-trypsin H5</td> <td>Chr19</td> <td>329</td> <td>-</td> <td>4</td> <td>240</td>	Inter-alpha-trypsin H5	Chr19	329	-	4	240
Trypsin-1 Chrl 1208 + 1 1018 Anionic trypsin-1 Chrl 831 - 1 703 Inter-alphat-trypsin H4 Chr3 3430 ? 1 3430 Chymotrypsinogen B Chr5 334 ? 1 3430 Chymotrypsin-Ike Elastase Chr5 315 ? 1 386 Anionic trypsin-2-like Chr5 448 + 1 386 Anionic trypsin-2-like Chr5 496 - 1 427 Trypsin eta Chr5 807 ? 2 593 Chymotrypsin-1 Chr10 7596 - 1 985 BPTI/Kunitz protein Chr10 7596 - 1 668 Trypsin-1 Chr12 646 ? 1 668 Trypsin-1ike Chr13 2764 - 2 345 Trypsin-1ike Chr13 540 ? 2 540 Trypsin opsilon Chr13 518 + 2 434	Inter-alpha-trypsin H6	Chr19	329	-	4	240
$\lambda^{homic trypsin-1}$ Chrl831-1703Inter-alpha-trypsin H4Chr33430?13430Chymotrypsin-1Chr5315?1334Chymotrypsin-1Chr5315?1315Chymotrypsin-1Chr5448+1386Anionic trypsin-2-likeChr5614+1451Anionic trypsin-2-likeChr5614+1427Trypsin taChr5807?2593Trypsin taChr5807?2593Chymotrypsin-likeChr107596-1646Chymotrypsin-likeChr12646?1646Chymotrypsin-likeChr132764-2345Trypsin-likeChr132764-2345Trypsin-likeChr13540?2540Trypsin 5C1Chr13540?2540Trypsin 5C1Chr13518+2434Trypsin 5C1Chr13518+2333Trypsin 5C1Chr13521?1501Trypsin 5C1Chr13521?1209Trypsin-1Chr13521?2521Trypsin-5Chr13640?1440Trypsin-5Chr13521?2521Trypsin-6Chr13521?2	Trypsin-1	Chr1	1208	+	1	1018
Intra-alpha ⁻ trypsin H4 Chr3 3430 ? 1 3430 Chymotrypsingen B Chr5 334 ? 1 334 Chymotrypsin-like Elastase Chr5 315 ? 1 315 Chymotrypsin B Chr5 448 + 1 386 Anionic trypsin-2-like Chr5 448 + 1 385 Anionic trypsin-2-like Chr5 496 - 1 427 Trypsin eta Chr5 807 ? 2 593 Chuptotrypsin-Jike Chr10 7596 - 1 385 Prypsin-Ia Chr12 646 ? 1 646 trypsin-like Chr13 6442 + 1 840 Trypsin-like Chr13 2764 - 2 345 Trypsin epsilon Chr13 540 ? 2 440 Trypsin sG1 Chr13 518 + 2 434	Anionic trypsin-1	Chr1	831	-	1	703
$\begin{array}{c} Chymotrysin-like Elastase \\ Chymotrysin-like Elastase \\ Chymotrysin-like Elastase \\ Chymotrysin B \\ Chr5 \\ 448 \\ + \\ 1 \\ 386 \\ Anionic trysin-2-like \\ Chr5 \\ 448 \\ + \\ 1 \\ 386 \\ Anionic trysin-2-like \\ Chr5 \\ 448 \\ + \\ 1 \\ 386 \\ Anionic trysin-2-like \\ Chr5 \\ 448 \\ + \\ 1 \\ 427 \\ Trysin eta \\ Chr5 \\ 807 \\ ? \\ 2 \\ 593 \\ Trysin eta \\ Chr5 \\ 807 \\ ? \\ 2 \\ 593 \\ Trysin eta \\ Chr10 \\ 7596 \\ - \\ 1 \\ 985 \\ PFT[Kunitz protein \\ Chr10 \\ 7596 \\ - \\ 1 \\ 985 \\ PFT[Kunitz protein \\ Chr10 \\ 445 \\ + \\ 1 \\ 385 \\ Trysin-1 \\ Chr12 \\ 668 \\ ? \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 1 \\ 668 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ $	Inter-alpha-trypsin H4	Chr3	3430	?	1	3430
Chymotrypsin-like Elastase Chr.5 315 ? 1 315 Chymotrypsin B Chr.5 448 + 1 386 Anionic trypsin-2-like Chr.5 614 + 1 427 Trypsin ta Chr.5 496 - 1 427 Trypsin eta Chr.5 807 ? 2 593 Chymotrypsin-like Chr.10 7596 - 1 985 PTI/Kunitz protein Chr10 445 + 1 385 Trypsin-like Chr12 666 ? 1 666 Trypsin-like Chr13 2764 - 2 345 Trypsin-like Chr13 540 ? 2 540 Trypsin psilon Chr13 540 ? 2 343 Trypsin psilon Chr13 518 + 2 343 Trypsin 5C1 Chr13 518 + 2 521 Trypsi	Chymotrypsinogen B	Chr5	334	?	1	334
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Chymotrypsin-like Elastase	Chr5	315	?	1	315
Anionic Trypsin-2-likeChr5 614 +1 545 Anionic trypsin-2-likeChr5 496 -1 427 Trypsin etaChr5 807 ?2 593 Trypsin etaChr5 807 ?2 593 Chymotrypsin-likeChr10 7596 -1 985 BPTI/Kunitz proteinChr10 445 +1 385 Trypsin-1Chr12 646 ?1 646 trypsin-1Chr13 6442 +1 840 Trypsin-likeChr13 2764 -2 345 Trypsin-gilonChr13 540 ?2 540 Trypsin epsilonChr13 540 ?2 540 Trypsin foG1Chr13 518 +2 434 Trypsin 5G1Chr13 518 +2 434 Trypsin 5G1Chr13 44817 -2 833 Trypsin 5G1Chr13 44817 -2 833 Trypsin 5G1Chr13 44817 -2 251 Trypsin 5Chr13 521 ?2 521 Trypsin 5Chr13 521 ?2 521 Trypsin 5Chr13 521 ?2 521 Trypsin 5Chr13 597 1 591 Trypsin 5Chr13 5412 - 6 2904 Ovochymas-2-likeChr15 9412 - 6 2904 </td <td>Chymotrypsin B</td> <td>Chr5</td> <td>448</td> <td>+</td> <td>1</td> <td>386</td>	Chymotrypsin B	Chr5	448	+	1	386
Anionic trypsin-2-likeChr5 496 -1 427 Trypsin etaChr5 807 ?2 593 Chymotrypsin-likeChr10 7596 -1 985 BPTUKunitz proteinChr10 445 +1 385 Trypsin-likeChr12 646 ?1 646 trypsin-likeChr13 6442 +1 840 Trypsin-likeChr13 2764 -2 345 Trypsin-likeChr13 540 ?2 540 Trypsin epsilonChr13 540 ?2 540 Trypsin filkChr13 540 ?2 540 Trypsin forChr13 540 ?2 540 Trypsin forChr13 518 +2 434 Trypsin forChr13 518 +2 434 Trypsin forChr13 44817 -2 833 Trypsin-1Chr13 440 ?1 440 Trypsin-5Chr13 143 ?1 1143 Trypsin-5Chr13 521 ?2 521 Trypsin-5Chr13 591 ?1 591 Trypsin-5Chr13 729 ?1 729 Trypsin-5Chr13 729 ?1 729 Trypsin-5Chr13 729 ?1 591 Trypsin-5Chr13 910 ?1 500 Cochym	Anionic trypsin-2-like	Chr5	614	+	1	545
Trypsin etaChr5 807 ?2 593 Trypsin etaChr5 807 ?2 593 Chymotrypsin-likeChr10 7596 -1 985 BPTI/Kunitz proteinChr10 445 +1 385 Trypsin-likeChr12 646 ?1 646 Trypsin-likeChr13 6442 +1 840 Trypsin-likeChr13 2764 -2 345 Trypsin-likeChr13 2764 -2 345 Trypsin-likeChr13 540 ?2 540 Trypsin epsilonChr13 540 ?2 540 Trypsin 5G1Chr13 518 +2 434 Trypsin 5G1Chr13 518 +2 833 Trypsin-1Chr13 44817 -2 833 Trypsin-1Chr13 518 +2 833 Trypsin-5Chr13 143 ?1 1443 Trypsin-1Chr13 521 ?2 521 Kalikrein-11Chr13 521 ?1 591 Trypsin-5Chr13 729 ?1 591 Trypsin-5Chr13 691 ?1 501 Covolnymase-2-likeChr15 9412 - 6 2904 Ovochymase-2-likeChr15 9412 - 6 2904 Ovochymase-2-likeChr15 9412 - 6 29	Anionic trypsin-2-like	Chr5	496	_	1	427
Trypsin eta $Chr5$ 807 ?2 593 $Chymotrypsin-like$ $Chr10$ 7596 -1 985 $Prypsin-like$ $Chr10$ 445 +1 385 $Trypsin-I$ $Chr12$ 646 ?1 646 $trypsin IP1-like$ $Chr12$ 668 ?1 646 $Trypsin-Ike$ $Chr13$ 6442 +1 840 $Trypsin-like$ $Chr13$ 2764 -2 345 $Trypsin-gsilon$ $Chr13$ 540 ?2 540 $Trypsin epsilon$ $Chr13$ 518 +2 434 $Trypsin fSG1$ $Chr13$ 518 +2 434 $Trypsin SG1$ $Chr13$ 518 +2 833 $Trypsin-1$ $Chr13$ 44817 -2 833 $Trypsin-5$ $Chr13$ 44817 -2 833 $Trypsin-5$ $Chr13$ 521 ?2 521 $Trypsin-5$ $Chr13$ 521 ?2 521 $Trypsin-5$ $Chr13$ 729 ?1 729 $Trypsin-5$ $Chr13$ 691 ?1 560 $Ovochymase-2-like$ $Chr15$ 9412 - 6 2904	Trypsin eta	Chr5	807	?	2	593
Chymotrypsin-like $Chr10$ 7596 $-$ 1 985 $BPTI/Kunitz protein$ $Chr10$ 445 $+$ 1 385 $Trypsin-1$ $Chr12$ 646 ?1 646 $Trypsin-like$ $Chr12$ 668 ?1 668 $Trypsin-like$ $Chr13$ 2764 $-$ 2 345 $Trypsin-like$ $Chr13$ 2764 $-$ 2 345 $Trypsin-like$ $Chr13$ 540 ?2 540 $Trypsin epsilon$ $Chr13$ 540 ?2 540 $Trypsin epsilon$ $Chr13$ 540 ?2 540 $Trypsin epsilon$ $Chr13$ 540 ?2 540 $Trypsin fSG1$ $Chr13$ 518 $+$ 2 434 $Trypsin 5G1$ $Chr13$ 44817 $-$ 2 833 $Trypsin-1$ $Chr13$ 44817 $-$ 2 833 $Trypsin-5$ $Chr13$ 440 ?1 440 $Trypsin-5$ $Chr13$ 1143 ?1 1143 $Trypsin-5$ $Chr13$ 729 ?1 729 $Trypsin-5$ $Chr15$ 9412 $ 6$ 2904 <t< td=""><td>Trypsin eta</td><td>Chr5</td><td>807</td><td>?</td><td>2</td><td>593</td></t<>	Trypsin eta	Chr5	807	?	2	593
BPTI/Kunitz protein $Chr10$ 445 +1 385 $Trypsin-1$ $Chr12$ 646 ?1 666 $Trypsin-1ike$ $Chr12$ 668 ?1 666 $Trypsin-like$ $Chr13$ 2764 -2 345 $Trypsin-like$ $Chr13$ 2764 -2 345 $Trypsin-gsilon$ $Chr13$ 2764 -2 345 $Trypsin epsilon$ $Chr13$ 540 ?2 540 $Trypsin soliton$ $Chr13$ 518 +2 434 $Trypsin 5G1$ $Chr13$ 518 +2 434 $Trypsin 5G1$ $Chr13$ 44817 -2 833 $Trypsin-5$ $Chr13$ 44817 -2 833 $Trypsin-5$ $Chr13$ 143 ?1 1143 $Trypsin-5$ $Chr13$ 521 ?2 521 $Trypsin-5$ $Chr13$ 521 ?2 521 $Trypsin-5$ $Chr13$ 729 ?1 729 $Trypsin-5$ $Chr13$ 691 ?1 560 $Ovochymase-2-like$ $Chr15$ 9412 - 6 2904 $Ovochymase-2-like$ $Chr15$ 9412 - 6 <	Chymotrypsin-like	Chr10	7596	-	1	985
Trypsin-1 trypsin IP1-likeChr12646?1646trypsin IP1-likeChr136442+1668Trypsin-likeChr132764-2345Trypsin-likeChr132764-2345Trypsin-likeChr132764-2345Trypsin epsilonChr13540?2540Trypsin epsilonChr13518+2434Trypsin 5G1Chr13518+2434Trypsin 5G1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr1344817-2833Trypsin-5Chr13440?11143Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13691?1591Trypsin-5Chr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr	BPTI/Kunitz protein	Chr10	445	+	1	385
trypsinIP1-likeChr12668?1668Trypsin-likeChr13 6442 +1840Trypsin-likeChr132764-2345Trypsin-likeChr132764-2345Trypsin-likeChr13540?2540Trypsin epsilonChr13540?2344Trypsin 5G1Chr13518+2434Trypsin 5G1Chr13518+2434Trypsin-1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr1344817-2833Trypsin-1Chr131143?11443Trypsin-1Chr13521?2521Trypsin-5Chr13521?2521Trypsin-5Chr13729?1591Trypsin-5Chr13560?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412	Trypsin-1	Chr12	646	?	1	646
Trypsin-likeChr13 6442 +1 840 Trypsin-likeChr13 2764 -2 345 Trypsin epsilonChr13 2764 -2 345 Trypsin epsilonChr13 540 ?2 540 Trypsin epsilonChr13 540 ?2 434 Trypsin 5C1Chr13 518 +2 434 Trypsin 5G1Chr13 518 +2 833 Trypsin-1Chr13 44817 -2 833 Trypsin-1Chr13 44817 -2 833 Trypsin-1Chr13 143 ?1 1143 Trypsin-5Chr13 521 ?2 521 Trypsin-5Chr13 521 ?2 521 Trypsin-5Chr13 521 ?2 521 Trypsin-5Chr13 691 ?1 591 Trypsin epsilonChr13 560 ?1 591 Trypsin epsilonChr15 9412 - 6 2904 Ovochymase-2-likeChr15 9412 </td <td>trypsin IP1-like</td> <td>Chr12</td> <td>668</td> <td>?</td> <td>1</td> <td>668</td>	trypsin IP1-like	Chr12	668	?	1	668
Trypsin-likeChr132764-2345Trypsin-likeChr132764-2345Trypsin epsilonChr13540?2540Trypsin epsilonChr13540?2344Trypsin epsilonChr13518+2434Trypsin 5G1Chr13518+2434Trypsin 5G1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr13440?11143Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13691?1591Trypsin-5Chr13691?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr1	Trypsin-like	Chr13	6442	+	1	840
Trypsin-likeChr13 2764 -2 345 Trypsin epsilonChr13 540 ?2 540 Trypsin epsilonChr13 540 ?2 540 Trypsin 5G1Chr13 518 +2 434 Trypsin 5G1Chr13 518 +2 833 Trypsin 5G1Chr13 44817 -2 833 Trypsin-1Chr13 44817 -2 833 Trypsin-5Chr13 44817 -2 833 Trypsin-1Chr13 521 ?1 440 Trypsin-5Chr13 521 ?2 521 Kallikrein-11Chr13 521 ?2 521 Trypsin-5Chr13 729 ?1 729 Trypsin-5Chr13 691 ?1 560 Ovochymase-2-likeChr15 9412 - 6 2904 Ovochymase-2-likeChr15<	Trypsin-like	Chr13	2764	-	2	345
Trypsin epsilonChr13540?2540Trypsin epsilonChr13540?2540Trypsin 5G1Chr13518+2434Trypsin 5G1Chr13518+2833Trypsin-1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr13440?1440Trypsin-5Chr131143?11143Trypsin-5Chr13521?2521Trypsin-5Chr13521?2521Trypsin-5Chr13691?1591Trypsin-5Chr13691?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr15<	Trypsin-like	Chr13	2764	-	2	345
Trypsin epsilonChr13540?2540Trypsin 5G1Chr13518+2434Trypsin 5G1Chr13518+2434Trypsin 5G1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr13440?1440Trypsin-5Chr131143?11143Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeC	Trypsin epsilon	Chr13	540	?	2	540
Trypsin 5G1Chr13518+2434Trypsin 5G1Chr13518+2434Trypsin 5G1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr13440?1440Trypsin 55Chr131143?11143Trypsin 5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-like	Trypsin epsilon	Chr13	540	?	2	540
Trypsin 5G1Chr13518+2434Trypsin-1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr13440?1440Trypsin-5Chr131143?11143Trypsin-5Chr13521?2521Kallikrin-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-like<	Trypsin 5G1	Chr13	518	+	2	434
Trypsin-1Chr1344817-2833Trypsin-1Chr1344817-2833Trypsin-5Chr13440?1440TrypsinChr131143?11143TrypsinChr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1501Trypsin-5Chr13691?1501Trypsin-5Chr13691?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr15 </td <td>Trypsin 5G1</td> <td>Chr13</td> <td>518</td> <td>+</td> <td>2</td> <td>434</td>	Trypsin 5G1	Chr13	518	+	2	434
Trypsin-1Chr13 44817 -2 833 Trypsin-5Chr13440?1440TrypsinChr131143?11143Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1591Trypsin-5Chr13560?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-422Ovochymase-2-likeChr159412-62904Ovochymase-	Trypsin-1	Chr13	44817	-	2	833
Trypsin-5Chr13440?1440TrypsinChr131143?11143Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1591Trypsin-5Chr13560?1501Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovoch	Trypsin-1	Chr13	44817	-	2	833
TrypsinChr131143?11143Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1591Trypsin epsilonChr13560?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-422Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-422Ovochymase-2-likeChr159412-422Ovochymase-2-likeChr159412-422<	Trypsin-5	Chr13	440	?	1	440
Trypsin-5Chr13521?2521Kallikrein-11Chr13521?2521Trypsin-5Chr13729?1729Trypsin-5Chr13691?1591Trypsin epsilonChr13560?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-427	Trypsin	Chr13	1143	?	1	1143
Kallikrein-11Chr13 521 ?2 521 Trypsin-5Chr13 729 ?1 729 Trypsin-5Chr13 691 ?1 591 Trypsin epsilonChr13 560 ?1 560 Ovochymase-2-likeChr15 9412 -6 2904 Ovochymase-2-likeChr15 9412 - 427	Trypsin-5	Chr13	521	?	2	521
Trypsin-5Chr13729?1729Trypsin-5Chr13691?1591Trypsin epsilonChr13560?1560Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-62904Ovochymase-2-likeChr159412-42204Ovochymase-2-likeChr159412-1427	Kallikrein-11	Chr13	521	?	2	521
Trypsin-5Chr13 691 ?1 591 Trypsin epsilonChr13 560 ?1 560 Ovochymase-2-likeChr15 9412 -6 2904 Trypsin-1Chr18 1467 +1 427	Trypsin-5	Chr13	729	?	1	729
Trypsin epsilon Chr13 560 ? 1 560 Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Trypsin-5	Chr13	691	?	1	591
Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Trypsin epsilon	Chr13	560	?	1	560
Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Ovochymase-2-like	Chr15	9412	_	6	2904
Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Ovochymase-2-like	Chr15	9412	-	6	2904
Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Ovochymase-2-like	Chr15	9412	_	6	2904
Ovochymase-2-like Chr15 9412 - 6 2904 Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Ovochymase-2-like	Chr15	9412	_	6	2904
Ovochymase-2-like Chr15 9412 - 6 2904 Trypsin-1 Chr18 1467 + 1 427	Ovochymase-2-like	Chr15	9412	_	6	2904
<i>Trypsin-1</i> Chr18 1467 + 1 427	Ovochymase-2-like	Chr15	9412	-	6	2904
	Trypsin-1	Chr18	1467	+	1	427

 Table 1. Trypsin genes identified in the Caligus rogercresseyi genome.



Figure 1. Identification of trypsin and bantam genes in the *C. rogercresseyi* genome through CIRCOS plot. Chr1–Chr21 colored segments correspond to the complete sequence of the chromosomes of the sea louse genome using a chromosome unit value of 100,000 bp. The first track (light blue) corresponds to a histogram plot of reads mapped in genes annotated as trypsin, trypsin-like, and chymotrypsins for this species. The second track (gray) shows the read mapping for annotated bantam miRNAs in the sea louse genome. Links correspond to syntenic blocks in the *C. rogercresseyi* genome obtained from blastN analyses of 10,000 bp segments throughout the whole genome.

On the other hand, 155 different mappings for miRNAs from reads assembled and annotated as members of the bantam family were obtained from the sea louse genome (Figure 1). These mappings were ubiquitously distributed in all the chromosomes, with more bantam in chromosomes 7 and 12. However, most of the mapped reads were located at chromosomes 13 and 16, followed by chromosome 6, which related to higher expression levels (Supplementary Table S1).

2.2. Expression Analyses of Bantam and Trypsin Genes

Expression differences were found in trypsin genes and bantam miRNAs in samples exposed to delousing drugs from susceptible and resistant populations (Figure 2). Expression differences were found in susceptible vs. resistant populations exposed to the same drug. From the 60 trypsin genes, there were expression differences according to resistant/susceptible populations in 46 genes (Figure 2B,C). Overall, there was a reduction in the mean expression of trypsin genes in susceptible populations than in resistant lice populations. There were 38 trypsin genes with expression patterns associated with the susceptible populations, including 14 that were differentially expressed only in these populations, including eight that were only differentially expressed in these populations, including the target of the susceptible populations. In addition,



24 trypsins were differentially expressed in lice exposed to drugs obtained from resistant and susceptible populations.

Figure 2. In silico expression analyses for trypsin (A–C) and bantam (D–F) in *C. rogercresseyi* exposed to delousing drugs. (A,D) Heatmaps for fold change values calculated on exposed samples vs. control for differentially expressed trypsin genes and bantam miRNAs, respectively. Significant expression changes were considered if the fold change > |4| and *p*-value > 0.01. (B,E) Violin plots of the mean expression values of all the differentially expressed trypsin genes and bantam miRNAs, respectively, separated by susceptible and resistant populations to delousing drugs. (C,F) Venn diagrams for trypsin genes and bantam miRNAs evaluated in (B,E) plots.

Regarding bantam miRNAs expression, a lower number of transcripts showed differential expression changes in sea lice, with a total of 26 bantams with a significant expression associated with either susceptible or resistant populations (Figure 2E,F). Bantam expression was also slightly reduced in susceptible populations compared to resistant populations for the three drugs. A total of 26 bantams had significant expression differences in lice exposed to drugs from the resistant populations, whereas 12 had expression patterns associated only with resistant populations. In contrast, 14 bantams' expression was observed in susceptible populations, including exclusive expression patterns in 8 miRNAs. Additionally, six bantam miRNAs were differentially expressed in lice exposed to drugs in susceptible and resistant populations. When trypsin and bantam expression levels were observed in heatmaps to find differences in single transcripts (Figure 2A,D), more contrasting differences in experimental groups (different drugs, or susceptible vs. resistant population comparisons) were found in bantam miRNAs than in trypsin genes. In these heatmaps, fold change values for bantam expression were closer to the limits of the scale than trypsin expression values.

2.3. Expression Value Correlations

From the 32 trypsin genes and 26 bantam miRNAs with expression patterns associated with resistant/susceptible populations, significant correlations in these expression profiles were obtained through Pearson's calculations and the corrplot package. Combining the

data obtained from the exposure for each of the three delousing drugs, a total of 53 significant correlations (|r| < 0.9; *p*-value < 0.05) were found in the expression of 23 different trypsin genes and 24 different bantam miRNAs (Figure 3). A total of 17 significant negative correlations (r < -0.9; *p*-value < 0.05) were obtained in these data. However, these data combined expression values obtained from different populations and exposure to three different drugs; therefore, some significant correlations could be missed. Using the expression data separated by each delousing drug, more significant correlations were obtained between trypsins and bantams and were associated with the exposure to each specific drug (see links in the CIRCOS plot in Figure 3). In the expression patterns of sea lice exposed to azamethiphos from both susceptible and resistant populations, 23 significant negative correlations were found (see blue links in Figure 3); 19 were found in samples exposed to deltamethrin (see green links in Figure 3); and 24 were found in lice exposed to cypermethrin (see red links in Figure 3). Even though trypsin genes and bantam miR-NAs are distributed in various chromosomes in the sea lice genome, these correlations were concentrated in a few chromosomes and delousing drugs. A total of 82.61% of negative correlations in populations exposed to azamethiphos were associated with trypsins found in chromosome 1 only, and the remaining 16.67% were associated with trypsins found in chromosome 4. In populations exposed to deltamethrin, negative correlations occurred in trypsins from only three chromosomes: 47.37% in chromosome 5, and 26.32% in chromosomes 1 and 13. In populations exposed to cypermethrin, most of the significant correlations were found in only two chromosomes: 45.83% in chromosome 13 and 37.50% in chromosome 1, and the remaining correlations in trypsins were from chromosomes 10 and 11, with 8.33% each.





Two trypsin genes (trypsins 2 and 5) and one bantam sequence were used to validate in silico expression data by qPCR. These three selected genes showed differential expression values in resistant and susceptible populations for the three delousing drugs (Figure 4). In the qPCR analysis results, bantam showed an increase in expression levels in the resistant population to azamethiphos after drug exposure and a reduction in expression in the susceptible population to deltamethrin after drug exposure. Significant variations between control and exposed samples were found in most of the experimental groups. The most significant variation in gene expression for trypsin 5 had an opposite trend with respect to bantam expression, where sea lice from the susceptible population reduced the expression levels after drug exposure. In contrast, the most relevant expression changes in the trypsin 2 gene were found in the samples from the populations exposed to cypermethrin. This latter gene presented an opposite trend to the expression of bantam miRNA, showing a reduction in expression in the exposed samples to azamethiphos and deltamethrin.



Figure 4. Validation of gene expression levels of bantam, trypsin-2, and trypsin-5 by qPCR analyses. Relative expression is calculated by $\Delta\Delta C_T$ values after normalization with the corresponding endogenous control (mir-2796 for bantam expression and b-tubulin for both trypsin genes). Light blue columns correspond to control sea louse samples, and light brown to samples exposed to the respective drug: "aza" = azamethiphos; "delta" = deltamethrin; "cyper" = cypermethrin. Error bars correspond to standard deviation. S: susceptible population; R: resistant population.

2.5. Validation of Trypsin Binding Site for Bantam through Luciferase Assay

Due to the opposite trends in the expression values from trypsin 2-like and bantam, trypsin 2-like was selected as a candidate for identifying binding sites for this miRNA and for validation through a luciferase assay. The whole transcript sequence used for trypsin 2 had a total length of 1937 nt, with an ORF region of 774 nt coding for 257 amino acids. The 5'-UTR and 3'-UTR regions were 686 nt and 477 nt, respectively (Figure 5A). The structural analysis of the deduced protein sequence showed a serine protease domain and a putative endopeptidase activity site (Figure 5B). Multiple alignments with trypsin proteins described for other arthropods showed a high conservation level (Figure 5B). This trypsin from *C. rogercresseyi* showed 39.47% and 47.86% identity with trypsin proteins described for trypsin 2 from *C. rogercresseyi* showed that this gene is in the clade for trypsins described in *C. clemensi* and two anionic trypsins previously described for *C. rogercresseyi* (Figure 5C).



Figure 5. Characterization of trypsin-2 gene in the sea louse *C. rogercresseyi*. (**A**) Schematic representation of full cDNA of trypsin-2 sequence. In red: peptide signal; in blue: trypsin-like serine protease domain. (**B**) Multiple alignments of trypsin-2 genes. Purple square represents the cleavage site, and yellow squares the substrate union site. The blue squares indicate the active site. (**C**) Phylogenetic analysis of trypsin-2 gene. The tree was constructed by neighbor joining methods, with 1000 bootstrap replicates.

A binding site for bantam was identified from the target prediction analysis on the trypsin 2-like 3'-UTR region. The binding sequence corresponded to 5-ACAGCTTTTTTAAG GTCTT-3, located between nucleotides 1016 and 1033 of the 3'-UTR (Figure 6A). The hybridization energy (Δ G) was estimated at -20.7 kcal/mol. The target sequence was cloned in the pmiGLO vector for functional validation and transfected with a bantam mimic in Hela cells (Figure 6B). After 48 h, the luciferase activity was reduced by 50% in the group transfected with the bantam mimic (Figure 6C). This result confirms the binding site of bantam as the trypsin 2-like 3'-UTR, suggesting a regulatory function of sea louse bantam miRNA in trypsin expression.



Figure 6. Validation of trypsin-2 target site for bantam miRNA. (**A**) The predicted binding site for bantam in 3' UTR of trypsin-2 gene. (**B**) Schematic representation of pmirGLO-3'UTR trypsin vector construction. (**C**) Luciferase assay showing luminescence activity after exposure of pmirGLO-3'UTR trypsin vector to bantam mimic sequence. The asterisk indicates significant differences (p < 0.001). Control samples correspond to the vector without the trypsin-2 gene insert.

3. Discussion

The impact of the sea lice species *C. rogercresseyi* and *L. salmonis* in the salmon farming industry represents one of the major concerns in the development of sustainable aquaculture. The reduction in the efficacy of therapeutic methods by anti-parasite drugs has motivated research focused on the emergence of pharmacological resistance through different perspectives. One described approach is identifying single mutations in the genes encoding for the target proteins of delousing drugs. In *L. salmonis*, targeted mutations in target genes have been associated with resistant populations [15], allowing the evaluation of the distribution of resistant genotypes to delousing drugs [16]. Regarding *C. rogercresseyi*, SNP polymorphisms have been described in the target gene for azamethiphos, with implications in the drug–protein active binding site [30]. However, these markers

10 of 17

have not been described yet in resistant populations for this species. Another strategy in *C. rogercresseyi* is to identify several genes and pathways related to drug response through next-generation sequencing and RNA-seq analyses [11]. Thus, the characterization of resistant genotypes has been enhanced by describing molecular functions that were not evaluated at first for assessing pharmacological resistance in the sea louse. Transcriptome analyses have also allowed the description of novel non-coding RNAs (long non-coding RNAs and miRNAs) associated with delousing drug response in *C. rogercresseyi*, expanding the knowledge to other overlooked genomic regions [11,28]. Nonetheless, the characterization of the complete genome of *C. rogercresseyi* at the chromosome scale [31] could reshape the understanding of pharmacological resistance and delousing drugs in this species.

Indeed, this is the first time that miRNA–gene interactions have been described combining co-expression and chromosome localization data to characterize the delousing drug response in sea lice species. Through the circular representation of the genome, the *bantam* and *trypsin* gene expression uncovered the potential interaction regions within a single chromosome or from regions present at different chromosomes. These interactions may be involved in the expression regulation of genes with a critical function in delousing drug response and the emergence of pharmacological resistance. Thus, the next step is to elucidate whether these *bantam–trypsin* interaction regions, particularly those involving two different chromosomes, are associated with genomic regions that could be interacting due to chromatin/chromosome organization in the cell (e.g., topologically associating domains, TAD).

Pharmacological resistance mechanisms are not only limited to punctual mutations in target genes for specific drugs. Complex and diverse gene pathways are activated or inhibited after exposure to delousing drugs [11,17,18,28,32]. One of the commonly described mechanisms present in arthropod species, and also suggested for sea lice, is metabolic resistance, whose mechanism involves drug detoxication systems including genes involved in the absorption, distribution, metabolism, and excretion of drugs [33]. Our study was focused on the family of *trypsin* genes, which are serine proteases involved in proteolysis but possessing a catalytic triad in their structure, similar to those found in carboxylesterases and other genes involved in drug detoxication [34]. In addition, the role of trypsin genes in insecticide resistance has been suggested in a previous study through drug degradation [35]. In C. rogercresseyi, 51 putative trypsin genes (44 trypsin-like and 7 chymotrypsin-like genes) were discovered from transcriptome databases, whose SNP markers and expression patterns suggested a role in the response of sea lice to deltamethrin [19]. This study expands the knowledge by identifying 60 trypsins and chymotrypsins and describing expression profiles in sea lice exposed to azamethiphos and cypermethrin. Another significant contribution is the expression patterns described in sea lice populations with contrasting resistance/susceptibility to the three drugs used in this study. The expression patterns associated with susceptible or resistant populations were localized at genomic regions where the *trypsin* gene was identified, providing novel information such as the finding of spliced variants for these genes. The next step is to characterize spliced variants associated with pharmacological resistance in this species. Interestingly, most of the trypsins identified in this study were differentially expressed after drug exposure and according to resistant or susceptible populations (46 out of 60 genes), supporting the hypothesis of the role of trypsins in delousing drug response and expanding this to azamethiphos, deltamethrin, and cypermethrin. These results also support the hypothesis related to considering *trypsin* genes as biomarkers for delousing drug susceptibility, which was suggested for C. rogercresseyi in novel bioassays using azamethiphos [36], especially trypsin-2 and trypsin-5, which were also validated by qPCR. In the qPCR validation of these two genes, the basal expression levels were also variable in control samples for both S/R populations (Figure 4). This is the reason to evaluate these genes as biomarkers not only considering unexposed samples but also exposed lice to drugs, and then to evaluate the differential expression of control vs. exposed samples in each population. The variations in the basal expression of these genes may be attributable to the different roles that *trypsins* could play in marine species, which

can be triggered, for example, by environmental conditions in seawater [37]. Moreover, variation in control samples was also found in a previous study in *C. rogercresseyi* [19].

The bantam miRNAs comprise a broad family described exclusively in arthropods, identified for the first time in *Drosophila* [38], with roles in tissular growth regulation [39], cell proliferation [40], and other biological processes mainly studied in *Drosophila* spp. [41–43]. This family was identified along with the description of the first miRNome for C. rogercresseyi, including the expression profiles of miRNAs in different developmental stages [26]. Around 200 isoforms of *bantam* (isomiRs) were found in the first characterization of the C. rogecrresseyi miRNome, and this was the most up-regulated family of miRNAs in the infective developmental stage of these parasites. Furthermore, *bantam* miRNAs had potential interactions with genes related to drug detoxication, such as the enzymes GST and Cytp450 and the transporter protein genes ABC and SLC [27]. These facts have led us to deeply study the *bantam* family as a candidate for delousing drug response in *C. rogercresseyi*. The first interesting point is that we only mapped 155 *miRNAs* on the sea lice genome, although more *bantam* sequences were found in transcriptome databases. This could be related to chromosome regions where the algorithm could not differentiate two very proximal bantam sequences in the genome due to the high conservation in the small sequences of these miRNAs. The next step to further describe *bantam* in the *C. rogercresseyi* genome is to evaluate the presence of spliced reads or variants corresponding to *bantam* sequences in the sea louse genome. Other interesting points for *bantam* expression patterns associated with delousing drugs compared with trypsins are the lower number of miRNAs with differential expression patterns from the total *bantams* identified, and the higher differences in fold change values. However, only 25% of the identified *bantam* miRNAs were differentially expressed, probably due to the diverse roles that these non-coding RNAs could play in the cell. Therefore, we used the 36 differentially expressed bantam miRNAs for further analyses, as these could be involved in delousing drug response in C. rogercresseyi.

Putative interactions between *trypsin* as the target gene and *bantam* miRNAs have been suggested in previous studies. In the sea louse, *C. rogercresseyi*, a potential target site was predicted in a *trypsin-3* gene for two *bantam* isoforms [26]. In that study, predicted target sites were found for *bantam* in the *serine protease* and *chymotrypsin-2* genes. A putative target site for *bantam* in another *chymotrypsin* gene was found in the salmon louse species in the Northern Hemisphere, *L. salmonis* [44]. In other arthropods, such as *Helicoverpa armigera*, predicted target sites have been found for *trypsin* and *chymotrypsin* genes, but also for other miRNAs not belonging to the *bantam* family [29,45]. None of these studies have focused on regulating the *trypsin* gene by *bantam* miRNA in the context of therapeutic drugs or pharmacological resistance. However, the significant contribution of the present study can be summarized in two aspects with respect to *trypsin* and *bantam* interactions: correlation of gene expression levels at spatial regions in the chromosomes of *C. rogercresseyi*, and validation of a *trypsin–bantam* target site by the luciferase assay.

Regarding correlation analyses, various correlations were found combining the data from exposure to the three drugs. However, the most interesting result is the negative correlations of gene expression for resistant and susceptible populations separated by drug and found in chromosome regions. Conversely to what was expected, significant correlations were found in different *bantam* and *trypsin* genes, even for deltamethrin and cypermethrin drugs which have similar structures since both are pyrethroid molecules [46]. These results could lead to identifying specific genomic regions involved in the resistance mechanisms for specific drugs. However, there are still chromosome regions of particular interest due to the greater number of *bantam–trypsin* interactions found, such as chromosomes 1, 12, and 13. On the other hand, regarding the luciferase assay, it was possible to validate the *trypsin 2-like* target site for *bantam*, which was a technique previously validated for other miRNA–mRNA binding sites [47]. Thus, the regulation of the expression of *trypsin-2* by *bantam* adds more value to the interest for this gene, which has been suggested as a biomarker for drug sensitivity in *C. rogercresseyi* [36]. Future investigation will be conducted to evaluate gene–miRNA interaction through in vivo assays, and to explore if *bantam* could reduce

the expression of the *trypsin-2* gene, altering the molecular response of the sea louse *C. rogercresseyi* to delousing drugs.

4. Materials and Methods

4.1. Identification of Trypsin Genes in Sea Louse Genome

The transcriptome database of the sea louse *Caligus rogercresseyi* exposed to three delousing drugs (azamethiphos, deltamethrin, and cypermethrin) was used to identify trypsin genes (transcriptomes in SRA database, accession number PRJNA559846). These samples corresponded to resistant and susceptible sea lice populations for each drug [11]. All the reads were mapped to the full genome of this species (Genome GenBank database accession number PRJNA551027) [31], using the CLC Genomic Workbench software (version 20.0, Qiagen Bioinformatics). In this software, the Large Gap Read Mapping tool was applied to map the trimmed reads from the transcriptomes on the 21 chromosomes of the reference genome using the following parameters: maximum number of hits for a segment = 10; maximum distance from seed = 50,000; match score = 1; mismatch cost = 2; insertion cost = 3; deletion cost = 3; length fraction = 0.8; similarity fraction = 0.8. The transcript discovery tool was used to predict genes using the following parameters: minimum length of ORF = 200; minimum unspliced reads = 5; gene merging distance = 50; minimum reads in gene = 10; minimum predicted gene length = 250. The obtained putative transcripts were blasted (blast-X) against a specific database from *trypsins* for arthropods obtained from non-redundant databases from GenBank and UniProt. Putative predicted *trypsin* genes that had *e*-values > 1×10^{-5} were considered for further analyses.

The identified *trypsin* genes were localized in the sea louse genome using the data from CLC Genomics software and by plotting them in a circular representation of the genome using the software CIRCOS [48]. Histograms of mapped reads per genomic position by each chromosome were plotted as a track into the circular visualization in this software. The karyotype of the *C. rogercresseyi* genome was used as a reference by defining each chromosome size, and the chromosome units were 100,000.

4.2. Identification of Bantam miRNAs in Sea Louse Genome

The small-RNA sequencing database from the same samples used in the previous section was used for these analyses (small-RNA Truseq libraries deposited in the same SRA project number PRJNA559846) [27]. The trimmed reads were mapped to the C. rogercresseyi genome in the CLC Genomics software using the following parameters: match score = 1; mismatch cost = 2; cost of insertions and deletions = linear gap cost and 3 for each; length fraction = 0.9; similarity fraction = 0.9. Mapped small-RNA reads were extracted by the "extract and count" tool in CLC Genomics, including ambiguous read and low-quality (>0.05) read filtering. Truseq sequencing adapters were also trimmed at this point, and all the reads were shorter than 15 nt and longer than 25 nt. Annotation of reads was conducted by merging counts and blast against miRbase (release 22.1), selecting species corresponding to arthropods, and allowing 2 maximum mismatches and 2 missing bases. Those sequences annotated as *bantam* were selected for further analyses from the list of putative miRNAs that passed all the cutoffs. The reads included in the individual assemblies that were annotated as "bantam" were extracted and mapped back to the genome of C. rogercresseyi to identify the localization of potential *bantam* mature sequences at the chromosome level. Putative bantam miRNAs were localized in the C. rogercresseyi genome by circular visualization in CIRCOS [48], following the same parameters used for *trypsin* and merging the plot in one analysis as a second track.

4.3. Expression Analyses of Trypsin and Bantam Genes

In silico expression analyses were conducted in the identified *trypsin* genes and *bantam* miRNAs in the CLC Genomic workbench. RNA-seq analyses were conducted using the samples exposed to different drugs and controls (GenBank project accession PRJNA559846), using *trypsin* as a reference, and miRNA-seq analyses were conducted using *bantam* as a

reference. For both analyses, expression values were expressed in TPM (total reads per million base pairs) and were calculated establishing a mismatch = 2, insert and deletion costs = 2, and length and similarity fractions = 0.8. Hierarchical clustering was conducted on both *trypsin* and *bantam* expression values to visualize changes in TPM values in all the samples, clustering the data by Euclidean distances with a complete linkage. Statistical analyses were based on generalized linear model regressions, automatically calculated on fold change values in CLC Genomics, and lice that were not exposed to drugs were used as control samples. Differentially expressed *trypsins* or *bantams* were considered if | fold change | < 4 and *p*-value > 0.01. Statistical comparisons were also estimated comparing resistant and susceptible populations by each delousing drug.

4.4. Gene Expression Validation by qPCR

The same samples used in a previous study of sea lice exposed to delousing drugs were used to validate RNA-seq and miRNA-seq analyses [11]. From this set of samples, control lice (not exposed to any drug) and lice exposed at 100 ppb of azamethiphos, 3 ppb of deltamethrin, and 15 ppb of cypermethrin were selected for validation by qPCR analyses. These concentrations corresponded to the recommended doses to apply in delousing drug treatments in Chile. Samples used in this analysis included lice from the resistant and susceptible populations for each drug. RNA extraction was conducted in all the samples using the Trizol reagent method (Invitrogen[®], Waltham, MA, USA), following the protocol provided by the manufacturer. Validation of trypsin gene transcription was conducted on 200 ng of extracted RNA, and cDNA synthesis was performed using the RevertAid H Minus First Strand cDNA Synthesis kit (ThermoFisher Scientific, Waltham, MA, USA). Primers and probes for the *trypsin 2* and 5 genes were used as in a previous study [36], including an endogenous control gene *b*-tubulin to perform a triplex TaqMan[®] assay (Table 2; Life TechnologiesTM, Carlsbad, CA, USA). The qPCR reactions consisted of 20 µL of total volume using the Kapa Probe fast qPCR Master Mix 2X kit (Kapa Biosystems, Wilmington, MA, USA) following the default protocol provided by the manufacturer. Thermal cycling conditions consisted of 95 °C for 3 min of initial denaturation, followed by 40 cycles of 95 °C for 3 s and 65 °C for 20 s, and the process was conducted in triplicates in a QuanStudio[™] 3 system (Life Technologies[™], Carlsbad, CA, USA).

Gene	Direction	Sequence (5'-3')	R (5′)	Q (3′)
B-tubulin	Forward	GGCTTCCAGCAACTACAACCG		
	Reverse	TTTCGTAAATAGGGTACCCGT		
	Probe	ACATGGCACTTGGGCCATGCG	HEX	BHQ1
Trypsin 2	Forward	CCAAGGTGACGGACCTTTGA		
• •	Reverse	AACGCTGTGACGAGGTTCAT		
	Probe	CCTAAAGGTTAGCCCCGAGG	FAM	BHQ1
Trypsin 5	Forward	TCCATGGTCCCAAGGCAAGTT		
	Reverse	CATTCGTTTGACCAAGGACCT		
	Probe	CGCCATCAATCCTCCGCCGCA	TAMRA	BHQ2
Bantam	Undirected	TCAGCGTTCACAATGATCTCA		
miR-2796	Undirected	GTGTCCCAATTATAATGTCCA		

Table 2. Primers and probes used for RT-qPCR expression analysis.

Validation of *bantam* transcription levels was achieved by synthesizing cDNA from the same RNA samples using the kit miSCript II RT (Qiagen, Hilden, Germany), with an incubation reaction at 37 °C for 60 min and 5 min at 95 °C. Specific primers were designed for *bantam* miRNA and were used for amplification by qPCR using the miScript SYBR Green PCR kit (Qiagen, Germany) in a QuanStudio 3 System (Life TechnologiesTM, Carlsbad, CA, USA). Thermal cycling conditions consisted of an initial denaturation and enzyme activation at 95 °C for 15 min, followed by 40 cycles of 94 °C for 15 s (denaturation), 55 °C for 30 s (annealing), and 70 °C for 45 s (extension). The *mir-2796* miRNA was used as an endogenous control for this reaction, as was previously validated for *C. rogercresseyi* exposed to delousing drugs [26]. For *trypsin* and *bantam* qPCR runs, the transcriptional activity was quantified using the $\Delta\Delta C_T$ comparative method previously described for gene expression analyses [49]. Statistical analyses from $\Delta\Delta C_T$ values corresponded to an application of a Kolmogorov test to evaluate the distribution of the obtained data, and then ordinary one-way ANOVA was used on data with a Gaussian distribution, or the Kruskal–Wallis test if that distribution was not achieved.

4.5. Trypsin–Bantam Interaction Analyses through Co-Expression and Target Prediction Analyses

The potential role of *trypsin* genes as targets for *bantam* miRNAs was evaluated through analyses of co-expression and target site prediction by sequence similarity and putative binding sites. Differentially expressed *trypsin* genes and *bantam* miRNAs were selected for both analyses. Pearson's correlation among TPM values from both datasets, including all the samples exposed and non-exposed to each drug, was calculated in the R software [50]. Plots for correlation analyses were constructed using the Corrplot package [51], considering as significant those correlations with *p*-value < 0.01. *Trypsins* and *bantams* with significant negative correlations (*p*-value < 0.01 and correlation value < -0.95) were included in the CIRCOS plot as links considering their genome localization. Only negative correlations were included because it was expected that miRNAs that regulate transcripts show opposite trends in gene expression.

Target prediction analyses were calculated using default parameters using two opensource software packages: RNA22 [52] and RNAHybrid [53]. Potential target sites for *bantam* miRNAs were considered if $\Delta G < -15$ and *p*-value < 0.05 in the algorithms from both programs.

4.6. Target Prediction Validation through Luciferase Assay

The 3'-UTR region identified for the *trypsin* 2 mRNA sequence was used as a template for *bantam* binding site prediction validation because it had the best ΔG and p-values. The binding site prediction was validated by functional analysis by Dual-Luciferase[®] Reporter Assay System (Promega, Madison, WI, USA). Briefly, the target sequence of trypsin 2 was cloned in a pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, USA). HeLa cell lines (CellZion SpA, Nueva Providencia, Chile, HeLa (ATCC CCL-2)) were seeded at 30.000 cells by well. After 48 h, cells were co-transfected with Lipofectamine 3000 (Invitrogen[®], Waltham, MA, USA) with the construction pmir-GLO-3UTR_trypsin-2 and a bantam mimic (aga-bantam mirVana (Ambion, Waltham, MA, USA). The sequence used for the *bantam* mimic corresponded to the same sequence used for qPCR validation analysis—TCAGCGTTCACAATGATCTCA, which correspond to a bantam-3 member. As a control group, HeLa cells were co-transfected with a pmir-GLO vector and *bantam* mimic. The luciferase activity was measured with the Dual-Luciferase[®] Reporter Assay System (Promega, USA) and normalized with Renilla. The assays were performed in triplicates. Statistical analysis was conducted through one-way ANOVA using the GraphPad Prism v9.0 software (GraphPad Software, Inc., San Diego, CA, USA).

5. Conclusions

The genes coding for *trypsin* and *chymotrypsin* and *bantam* miRNAs were identified throughout the genome of the sea louse *C. rogercresseyi*. Expression patterns in susceptible and resistant sea lice populations to azamethiphos, deltamethrin, and cypermethrin molecules, correlations of expression trends between *trypsin* genes and *bantam* miRNAs, and target prediction validation by the luciferase assay demonstrated a tight molecular interaction between *bantam* miRNAs and *trypsin* genes, especially the *trypsin-2* gene. The regulation of the expression of *trypsin* genes by a *bantam* suggests that this miRNA could be involved in the drug sensitivity of the sea louse *C. rogercresseyi*. Further studies will be needed to confirm the role of *bantam-trypsin* interactions on the emergence of the pharmacological resistance of these parasite species.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/ 10.3390/ncrna7040076/s1, Table S1: Mapped reads corresponding to bantam miRNAs on the *C. rogercresseyi* and annotation using two miRNAs databases.

Author Contributions: Conceptualization, G.N.-A. and C.G.-E.; experiments and methodology, C.C.-N., C.S.-V. and B.P.B.; statistical analyses, C.S.-V. and G.N.-A.; bioinformatic analyses, G.N.-A., D.V.-M. and V.V.-M., original draft preparation, G.N.-A., V.V.-M., B.P.B. and C.C.-N.; leading of final draft, G.N.-A.; review and editing, V.V.-M., C.G.-E. and D.V.-M.; resources, G.N.-A. and C.G.-E. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by FONDECYT #1210852, FONDECYT #11200813, and FONDAP #15110027, granted by CONICYT-Chile.

Data Availability Statement: The assembled genome used for sequence mapping and annotation has been deposited to the NCBI Assembly with the accession number ASM1338718v1 (Genbank project accession number: PRJNA551027). The transcriptome (mRNA-seq and small-RNA-seq) sequences used to identify *trypsin* and *bantam* sequences are deposited in the Sequence Read Archive (SRA) of NCBI Genbank under the accession code PRJNA559846.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Gallardo-Escárate, C.; Arriagada, G.; Carrera, C.; Gonçalves, A.T.; Nuñez-Acuña, G.; Valenzuela-Miranda, D.; Valenzuela-Muñoz, V. The race between host and sea lice in the Chilean salmon farming: A genomic approach. *Rev. Aquac.* **2019**, *11*, 325–339. [CrossRef]
- 2. Pike, A. Sea lice—Major pathogens of farmed Atlantic salmon. *Parasitol. Today* **1989**, *5*, 291–297. [CrossRef]
- 3. Costello, M.J. How sea lice from salmon farms may cause wild salmonid declines in Europe and North America and be a threat to fishes elsewhere. *Proc. R. Soc. B: Boil. Sci.* **2009**, *276*, 3385–3394. [CrossRef]
- 4. Costello, M.J. The global economic cost of sea lice to the salmonid farming industry. J. Fish Dis. 2009, 32, 115–118. [CrossRef] [PubMed]
- 5. Dresdner, J.; Chávez, C.; Quiroga, M.; Jiménez, D.; Artacho, P.; Tello, A. Impact of Caligus treatments on unit costs of heterogeneous salmon farms in Chile. *Aquac. Econ. Manag.* 2019, 23, 1–27. [CrossRef]
- 6. Roth, M.; Richards, R.H.; Sommerville, C. Current practices in the chemotherapeutic control of sea lice infestations in aquaculture: A review. *J. Fish Dis.* **1993**, *16*, 1–26. [CrossRef]
- 7. Liu, Y.; Bjelland, H. Estimating costs of sea lice control strategy in Norway. Prev. Vet.-Med. 2014, 117, 469–477. [CrossRef]
- 8. Aaen, S.M.; Helgesen, K.O.; Bakke, M.J.; Kaur, K.; Horsberg, T.E. Drug resistance in sea lice: A threat to salmonid aquaculture. *Trends Parasitol.* **2015**, *31*, 72–81. [CrossRef]
- 9. Marín, S.; Ibarra, R.; Medina, M.; Jansen, P. Sensitivity of Caligus rogercresseyi (Boxshall and Bravo 2000) to pyrethroids and azamethiphos measured using bioassay tests—A large scale spatial study. *Prev. Vet.-Med.* **2015**, *122*, 33–41. [CrossRef]
- Arriagada, G.; Figueroa, J.; Marín, S.L.; Arriagada, A.M.; Lara, M.; Gallardo-Escárate, C. First report of the reduction in treatment efficacy of the organophosphate azamethiphos against the sea lice Caligus rogercresseyi (Boxshall & Bravo, 2000). *Aquac. Res.* 2019, 51, 436–439. [CrossRef]
- Núñez-Acuña, G.; Sáez-Vera, C.; Valenzuela-Muñoz, V.; Valenzuela-Miranda, D.; Arriagada, G.; Gallardo-Escárate, C. Tackling the Molecular Drug Sensitivity in the Sea Louse *Caligus rogercresseyi* Based on mRNA and lncRNA Interactions. *Genes* 2020, 11, 857. [CrossRef]
- 12. Bass, C.; Field, L. Gene amplification and insecticide resistance. Pest Manag. Sci. 2011, 67, 886–890. [CrossRef]
- 13. Colmegna, B.; Morosi, L.; D'Incalci, M. Molecular and pharmacological mechanisms of drug resistance: An evolving paradigm. In *Mechanisms of Drug Resistance in Cancer Therapy*; Springer: Berlin/Heidelberg, Germany, 2017; pp. 1–12.
- 14. Faucon, F.; Gaude, T.; Dusfour, I.; Navratil, V.; Corbel, V.; Juntarajumnong, W.; Girod, R.; Poupardin, R.; Boyer, F.; Reynaud, S.; et al. In the hunt for genomic markers of metabolic resistance to pyrethroids in the mosquito Aedes aegypti: An integrated next-generation sequencing approach. *PLoS Negl. Trop. Dis.* **2017**, *11*, e0005526. [CrossRef] [PubMed]
- 15. Kaur, K.; Jansen, P.A.; Aspehaug, V.T.; Horsberg, T.E. Phe362Tyr in AChE: A Major Factor Responsible for Azamethiphos Resistance in Lepeophtheirus salmonis in Norway. *PLoS ONE* **2016**, *11*, e0149264. [CrossRef] [PubMed]
- 16. Fjørtoft, H.B.; Nilsen, F.; Besnier, F.; Stene, A.; Tveten, A.-K.; Bjørn, P.A.; Aspehaug, V.T.; Glover, K.A. Losing the 'arms race': Multiresistant salmon lice are dispersed throughout the North Atlantic Ocean. *R. Soc. Open Sci.* **2021**, *8*. [CrossRef]
- 17. Valenzuela-Muñoz, V.; Chavez-Mardones, J.; Gallardo-Escárate, C. RNA-seq analysis evidences multiple gene responses in Caligus rogercresseyi exposed to the anti-salmon lice drug azamethiphos. *Aquaculture* **2015**, *446*, 156–166. [CrossRef]
- Valenzuela-Muñoz, V.; Sturm, A.; Gallardo-Escárate, C. Transcriptomic insights on the ABC transporter gene family in the salmon louse Caligus rogercresseyi. *Parasites Vectors* 2015, *8*, 209. [CrossRef]
- Valenzuela-Miranda, D.; Gallardo-Escárate, C. Caligus rogercresseyi serine proteases: Transcriptomic analysis in response to delousing drugs treatments. *Aquaculture* 2016, 465, 65–77. [CrossRef]

- 20. Fast, M.D.; Johnson, S.C.; Eddy, T.D.; Pinto, D.; Ross, N.W. Lepeophtheirus salmonis secretory/excretory products and their effects on Atlantic salmon immune gene regulation. *Parasite Immunol.* **2007**, *29*, 179–189. [CrossRef]
- 21. Lehiy, C.J.; Drolet, B.S. The salivary secretome of the biting midge, Culicoides sonorensis. PeerJ 2014, 2, e426. [CrossRef]
- 22. Haenisch, S.; Cascorbi, I. miRNAs as mediators of drug resistance. *Epigenomics* **2012**, *4*, 369–381. [CrossRef] [PubMed]
- Etebari, K.; Afrad, M.H.; Tang, B.; Silva, R.; Furlong, M.J.; Asgari, S. Involvement of microRNA miR-2b-3p in regulation of metabolic resistance to insecticides inPlutella xylostella. *Insect Mol. Biol.* 2018, 27, 478–491. [CrossRef]
- 24. Hong, S.; Guo, Q.; Wang, W.; Hu, S.; Fang, F.; Lv, Y.; Yu, J.; Zou, F.; Lei, Z.; Ma, K.; et al. Identification of differentially expressed microRNAs in Culex pipiens and their potential roles in pyrethroid resistance. *Insect Biochem. Mol. Biol.* 2014, 55, 39–50. [CrossRef]
- 25. Lei, Z.; Lv, Y.; Wang, W.; Guo, Q.; Zou, F.; Hu, S.; Fang, F.; Tian, M.; Liu, B.; Liu, X.; et al. MiR-278-3p regulates pyrethroid resistance in Culex pipiens pallens. *Parasitol. Res.* **2014**, *114*, 699–706. [CrossRef]
- Gallardo-Escárate, C.; Valenzuela-Muñoz, V.; Boltaña, S.; Nuñez-Acuña, G.; Valenzuela-Miranda, D.; Gonçalves, A.; Détrée, C.; Tarifeño-Saldivia, E.; Farlora, R.; Roberts, S.; et al. The Caligus rogercresseyi miRNome: Discovery and transcriptome profiling during the sea lice ontogeny. *Agri Gene* 2017, *4*, 8–22. [CrossRef]
- Núñez-Acuña, G.; Valenzuela-Muñoz, V.; Valenzuela-Miranda, D.; Gallardo-Escárate, C. Comprehensive Transcriptome Analyses in Sea Louse Reveal Novel Delousing Drug Responses Through MicroRNA regulation. *Mar. Biotechnol.* 2021, 23, 710–723. [CrossRef] [PubMed]
- 28. Valenzuela-Miranda, D.; Etebari, K.; Asgari, S.; Gallardo-Escárate, C. Long noncoding RNAs: Unexplored players in the drug response of the sea louse Caligus rogercresseyi. *Agri Gene* **2017**, *4*, 1–7. [CrossRef]
- Lomate, P.R.; Mahajan, N.S.; Kale, S.M.; Gupta, V.S.; Giri, A.P. Identification and expression profiling of Helicoverpa armigera microRNAs and their possible role in the regulation of digestive protease genes. *Insect Biochem. Mol. Biol.* 2014, 54, 129–137. [CrossRef]
- 30. Agusti-Ridaura, C.; Dondrup, M.; Horsberg, T.E.; Leong, J.; Koop, B.F.; Bravo, S.; Mendoza, J.; Kaur, K. Caligus rogercresseyi acetylcholinesterase types and variants: A potential marker for organophosphate resistance. *Parasites Vectors* **2018**, *11*, 570. [CrossRef]
- Gallardo-Escárate, C.; Valenzuela-Muñoz, V.; Nuñez-Acuña, G.; Valenzuela-Miranda, D.; Gonçalves, A.T.; Escobar-Sepulveda, H.; Liachko, I.; Nelson, B.; Roberts, S.; Warren, W. Chromosome-scale genome assembly of the sea louse Caligus rogercresseyi by SMRT sequencing and Hi-C analysis. *Sci. Data* 2021, *8*, 60. [CrossRef] [PubMed]
- 32. Poley, J.D.; Braden, L.M.; Messmer, A.M.; Igboeli, O.O.; Whyte, S.K.; Macdonald, A.; Rodriguez, J.; Gameiro, M.; Rufener, L.; Bouvier, J.; et al. High level efficacy of lufenuron against sea lice (Lepeophtheirus salmonis) linked to rapid impact on moulting processes. *Int. J. Parasitol. Drugs Drug Resist.* **2018**, *8*, 174–188. [CrossRef]
- Schröder, A.; Klein, K.; Winter, S.; Schwab, M.; Bonin, M.; Zell, A.; Zanger, U.M. Genomics of ADME gene expression: Mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. *Pharm. J.* 2011, *13*, 12–20. [CrossRef]
- 34. Dorrah, M.; Elmelegi, M.; Bassal, T. Trypsin-and chymotrypsin esterase-like activity in the midgut regions of the larval Parasarcophaga hertipes (Sarcophagidae, Cyclorrhapha, Diptera). *Efflatoun's J. Entomol.* **2008**, *8*, 1–8.
- 35. Xiong, C.; Fang, F.; Chen, L.; Yang, Q.; He, J.; Zhou, D.; Shen, B.; Ma, L.; Sun, Y.; Zhang, D.; et al. Trypsin-Catalyzed Deltamethrin Degradation. *PLoS ONE* 2014, *9*, e89517. [CrossRef] [PubMed]
- 36. Sáez-Vera, C.; Núñez-Acuña, G.; Gallardo-Escárate, C. Sensitivity assessment to azamethiphos by time-to-response bioassay and biomarkers in the sea louse Caligus rogercresseyi. *Aquaculture* **2021**, *546*, 737340. [CrossRef]
- 37. Rungruangsak-Torrissen, K.; Moss, R.; Andresen, L.H.; Berg, A.; Waagbo, R. Different expressions of trypsin and chymotrypsin in relation to growth in Atlantic salmon (Salmo salar L.). *Fish Physiol. Biochem.* **2006**, *32*, 7–23. [CrossRef]
- 38. Hipfner, D.R.; Weigmann, K.; Cohen, S.M. The bantam Gene Regulates Drosophila Growth. *Genetics* 2002, 161, 1527–1537. [CrossRef]
- 39. Banerjee, A.; Roy, J.K. Dicer-1 regulates proliferative potential of Drosophila larval neural stem cells through bantam miRNA based down-regulation of the G1/S inhibitor Dacapo. *Dev. Biol.* **2017**, *423*, 57–65. [CrossRef]
- 40. Huang, H.; Li, J.; Hu, L.; Ge, L.; Ji, H.; Zhao, Y.; Zhang, L. Bantam is essential for Drosophila intestinal stem cell proliferation in response to Hippo signaling. *Dev. Biol.* 2014, 385, 211–219. [CrossRef]
- 41. Brennecke, J.; Hipfner, D.R.; Stark, A.; Russell, R.B.; Cohen, S.M. Bantam Encodes a Developmentally Regulated microRNA that Controls Cell Proliferation and Regulates the Proapoptotic Gene hid in Drosophila. *Cell* **2003**, *113*, 25–36. [CrossRef]
- 42. Nolo, R.; Morrison, C.M.; Tao, C.; Zhang, X.; Halder, G. The bantam MicroRNA Is a Target of the Hippo Tumor-Suppressor Pathway. *Curr. Biol.* **2006**, *16*, 1895–1904. [CrossRef] [PubMed]
- 43. Herranz, H.; Hong, X.; Cohen, S.M. Mutual Repression by Bantam miRNA and Capicua Links the EGFR/MAPK and Hippo Pathways in Growth Control. *Curr. Biol.* **2012**, *22*, 651–657. [CrossRef]
- 44. Núñez-Acuña, G.; Gallardo-Escárate, C. Characterization of the salmon louse Lepeophtheirus salmonis miRNome: Sex-biased differences related to the coding and non-coding RNA interplay. *Mar. Genom.* **2019**, *45*, 38–47. [CrossRef] [PubMed]
- 45. Jayachandran, B.; Hussain, M.; Asgari, S. An insect trypsin-like serine protease as a target of microRNA: Utilization of microRNA mimics and inhibitors by oral feeding. *Insect Biochem. Mol. Biol.* **2013**, *43*, 398–406. [CrossRef]
- 46. Katsuda, Y. Progress and Future of Pyrethroids. Top. Curr. Chem. 2011, 314, 1–30. [CrossRef]

- 47. Jin, Y.; Chen, Z.; Liu, X.; Zhou, X. Evaluating the microRNA targeting sites by luciferase reporter gene assay. In *MicroRNA Protocols*; Springer: Berlin/Heidelberg, Germany, 2013; pp. 117–127.
- 48. Krzywinski, M.; Schein, J.; Birol, I.; Connors, J.; Gascoyne, R.; Horsman, D.; Jones, S.J.; Marra, M.A. Circos: An information aesthetic for comparative genomics. *Genome Res.* 2009, 19, 1639–1645. [CrossRef]
- 49. Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* **2001**, 29, e45. [CrossRef] [PubMed]
- 50. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2021.
- 51. Wei, T.; Simko, V.; Levy, M.; Xie, Y.; Jin, Y.; Zemla, J. Package 'corrplot'. Statistician 2017, 56, 316–324.
- 52. Miranda, K.C.; Huynh, T.; Tay, Y.; Ang, Y.-S.; Tam, W.L.; Thomson, A.M.; Lim, B.; Rigoutsos, I. A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes. *Cell* **2006**, *126*, 1203–1217. [CrossRef]
- Rehmsmeier, M.; Steffen, P.; Höchsmann, M.; Giegerich, R. Fast and effective prediction of microRNA/target duplexes. RNA 2004, 10, 1507–1517. [CrossRef] [PubMed]